Wellington Shields Capital Management LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,105 shares of the medical research company’s stock, valued at approximately $969,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Beach Investment Management LLC. increased its position in Thermo Fisher Scientific by 1,702.8% in the 2nd quarter. Beach Investment Management LLC. now owns 71,661 shares of the medical research company’s stock valued at $12,503,000 after acquiring an additional 67,686 shares during the period. Synovus Financial Corp increased its position in Thermo Fisher Scientific by 37.3% in the 2nd quarter. Synovus Financial Corp now owns 3,470 shares of the medical research company’s stock valued at $603,000 after acquiring an additional 943 shares during the period. Rosenblum Silverman Sutton S F Inc. CA increased its position in Thermo Fisher Scientific by 0.3% in the 2nd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 43,958 shares of the medical research company’s stock valued at $7,669,000 after acquiring an additional 145 shares during the period. Baltimore Capital Management Inc. acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $209,000. Finally, Meiji Yasuda Life Insurance Co increased its position in Thermo Fisher Scientific by 0.4% in the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 23,256 shares of the medical research company’s stock valued at $4,057,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 86.31% of the company’s stock.
TMO has been the topic of several recent research reports. Bank of America boosted their price target on Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. BTIG Research initiated coverage on Thermo Fisher Scientific in a research report on Friday, January 5th. They issued a “buy” rating and a $230.00 price target on the stock. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a research report on Tuesday, October 31st. Leerink Swann restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Monday, October 30th. Finally, Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Two investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $220.50.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The company had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the previous year, the firm posted $2.41 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 annualized dividend and a yield of 0.34%. Thermo Fisher Scientific’s payout ratio is presently 10.71%.
In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 33,327 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares in the company, valued at approximately $13,285,478.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The disclosure for this sale can be found here. Insiders have sold a total of 144,327 shares of company stock worth $28,680,042 in the last quarter. 0.49% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.com-unik.info/2018/02/09/5105-shares-in-thermo-fisher-scientific-inc-tmo-purchased-by-wellington-shields-capital-management-llc.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.